IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.
|Videos|September 15, 2019
Dr. Usmani on Impact of BCMA on the Myeloma Treatment Landscape
Author(s)Saad Z. Usmani, MD, FACP
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.
Advertisement
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses how the target BCMA is impacting the multiple myeloma treatment landscape.
Advertisement
Related to this article
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Retrospective data tie longer survival with niraparib maintenance to homologous recombination deficiency after complete primary debulking.
Exploratory BEHOLD-1 data show responses to mocertatug rezetecan in platinum-resistant ovarian cancer across B7-H4 expression levels.
Updated BEHOLD-1 data show mocertatug rezetecan at its selected dose produced lasting responses in platinum-resistant ovarian cancer.
The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
3
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5